{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["190(2)"],"submitter":["Armand P"],"funding":["Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA"],"journal":["British journal of haematology"],"pagination":["e117-e120"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7496875"],"repository":["biostudies-literature"],"pubmed_title":["Pembrolizumab in relapsed or refractory Richter syndrome."],"pmcid":["PMC7496875"],"funding_grant_id":["N/A"],"pubmed_authors":["Christian B","Marinello P","Eichhorst B","Murawski N","Zain J","Chatterjee A","Phillips T","Stathis A","Hawkes EA","Svoboda J","Armand P","Pagel JM","Gulbas Z","Molin D","Ribrag V","Orlowski R"],"additional_accession":[]},"is_claimable":false,"name":"Pembrolizumab in relapsed or refractory Richter syndrome.","description":null,"dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2025-04-04T23:03:57.687Z","creation":"2025-04-04T23:03:57.687Z"},"accession":"S-EPMC7496875","cross_references":{"pubmed":["32544980"],"doi":["10.1111/bjh.16762"]}}